CLINICAL TRIALS PROFILE FOR ARRANON
✉ Email this page to a colleague
All Clinical Trials for ARRANON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | Children's Cancer Group | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00005080 ↗ | 506U78 in Treating Patients With Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2000-05-01 | Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die |
| NCT00005950 ↗ | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-04-01 | Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die |
| NCT00005982 ↗ | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-04-01 | Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma |
| NCT00016302 ↗ | Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | National Cancer Institute (NCI) | N/A | 2001-04-01 | Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia |
| NCT00408005 ↗ | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Active, not recruiting | National Cancer Institute (NCI) | Phase 3 | 2007-01-22 | This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. After a common induction therapy, patients were risk assigned and eligible for one or both post-induction randomizations: Escalating dose Methotrexate versus High Dose Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High Risk and induction failures. Standard risk patients did not receive nelarabine, High risk T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures were assigned to receive Nelarabine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARRANON
Condition Name
| Condition Name for ARRANON | |
| Intervention | Trials |
| Recurrent Adult T-cell Leukemia/Lymphoma | 2 |
| Angioimmunoblastic T-cell Lymphoma | 2 |
| T Acute Lymphoblastic Leukemia | 2 |
| Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ARRANON
Trials by Country
Clinical Trial Progress for ARRANON
Clinical Trial Phase
Clinical Trial Sponsors for ARRANON
Sponsor Name
